Patient enrollment in an international Phase III trial for Teva’s popular MS drug, Copaxone. The are over 1,400 patients enrolled at 180 sites in the US, Europe, Central Eastern Europe and Israel. The phase is meant to evaluate the efficacy, safety and tolerability of 40mg COPAXONE (glatiramer acetate injection) administered three times a week compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS) by capturing the total number of confirmed relapses during a 12-month placebo-controlled phase.
Results from the trial are expected in the second quarter of 2012.
Copaxone is approved in more than 50 countries worldwide, including the US, Russia, Canada, Mexico, Australia, Israel and all European countries for the treatment of multiple sclerosis.
In North America, COPAXONE is marketed by Teva Neuroscience, which is a subsidiary of Teva Pharmaceutical Industries.
In Europe, the product is marketed by Teva Pharmaceutical Industries and sanofi-aventis.